A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
Public ClinicalTrials.gov record NCT01218009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a one-year study to look at the safety of a dry powder inhaler with albuterol. After a one-week run in, for the first 3 months subjects will use an inhaler with either albuterol or a dummy drug at regular times four times a day. Then for the last nine months of the study, all subjects will be given the albuterol dry powder inhaler and will use it only when needed to help with breathing problems. Subjects will need to keep a daily diary (both paper and electronic) throughout the study recording any inhaler use and health problems. There will be visits to the study doctor about once a month for a year. This study is intended to show that the albuterol dry powder inhaler works well and is safe for use over a long period of time.
Study identification
- NCT ID
- NCT01218009
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 331 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2010
- Primary completion
- Nov 30, 2010
- Completion
- Nov 30, 2010
- Last update posted
- May 19, 2015
2010
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Clinical Study Site | Scottsdale | Arizona | — | — |
| Teva Clinical Study Site | Los Angeles | California | — | — |
| Teva Clinical Study Site | San Diego | California | — | — |
| Teva Clinical Study Site | Centennial | Colorado | — | — |
| Teva Clinical Study Site | Denver | Colorado | — | — |
| Teva Clinical Study Site | Miami | Florida | — | — |
| Teva Clinical Study Site | Gainesville | Georgia | — | — |
| Teva Clinical Study Site | Louisville | Kentucky | — | — |
| Teva Clinical Study Site | Wheaton | Maryland | — | — |
| Teva Clinical Study Site | Minneapolis | Minnesota | — | — |
| Teva Clinical Study Site | Plymouth | Minnesota | — | — |
| Teva Clinical Study Site | St Louis | Missouri | — | — |
| Teva Clinical Study Site | Bellevue | Nebraska | — | — |
| Teva Clinical Study Site | Boys Town | Nebraska | — | — |
| Teva Clinical Study Site | Skillman | New Jersey | — | — |
| Teva Clinical Study Site | Rochester | New York | — | — |
| Teva Clinical Study Site | Rockville Centre | New York | — | — |
| Teva Clinical Study Site | High Point | North Carolina | — | — |
| Teva Clinical Study Site | Raleigh | North Carolina | — | — |
| Teva Clinical Study Site | Canton | Ohio | — | — |
| Teva Clinical Study Site | Cincinnati | Ohio | — | — |
| Teva Clinical Study Site | Sylvania | Ohio | — | — |
| Teva Clinical Study Site | Eugene | Oregon | — | — |
| Teva Clinical Study Site | Portland | Oregon | — | — |
| Teva Clinical Study Site | El Paso | Texas | — | — |
| Teva Clinical Study Site | New Braunfels | Texas | — | — |
| Teva Clinical Study Site | San Antonio | Texas | — | — |
| Teva Clinical Study Site | Burke | Virginia | — | — |
| Teva Clinical Study Site | Seattle | Washington | — | — |
| Teva Clinical Study Site | Greenfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01218009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2015 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01218009 live on ClinicalTrials.gov.